Island Pharmaceuticals Ltd ASX: ILA Share Price & Review

ILA Overview

ILA Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Weak

GARP

Very Weak

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Very Weak

Growth

Earnings

Very Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About ILA

Website

N/A

Telephone

N/A

Address

Description

Island Pharmaceuticals Ltd. is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections. Its Isla101, a drug being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. The company was founded by David Foster on May 25, 2020 and is headquartered in Camberwell, Australia.

ILA Price Chart

Key Stats

Market Cap

AU$90.09M

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.08 - 0.38

Trade Value (12mth)

AU$18,094.00

1 week

20.34%

1 month

97.22%

YTD

115.15%

1 year

355.13%

All time high

0.62

Key Fundamentals

EPS 3 yr Growth

-24.20%

EBITDA Margin

N/A

Operating Cashflow

-$3m

Free Cash Flow Return

-63.80%

ROIC

-90.40%

Interest Coverage

-149.20

Quick Ratio

22.30

Other Data

Shares on Issue (Fully Dilluted)

200m

HALO Sector

Healthcare

Next Company Report Date

27-Aug-26

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.19

ILA Announcements

Latest Announcements

Date	Announcements
18 September 25	Investor webinar × Investor webinar
17 September 25	Investor presentation - Galidesivir update × Investor presentation - Galidesivir update
09 September 25	Application for quotation of securities - ILA × Application for quotation of securities - ILA
09 September 25	Cleansing Notice × Cleansing Notice
05 September 25	Letter to Shareholders, Notice of AGM & Proxy Form × Letter to Shareholders, Notice of AGM & Proxy Form
01 September 25	FDA meeting request lodged for Galidesivir × FDA meeting request lodged for Galidesivir
29 August 25	Preliminary Final Report × Preliminary Final Report
29 August 25	Annual Report to shareholders × Annual Report to shareholders
29 August 25	Appendix 4G and Corporate Governance Statement × Appendix 4G and Corporate Governance Statement
29 August 25	Annual Report to shareholders (incl auditor independence) × Annual Report to shareholders (incl auditor independence)
15 August 25	Change in substantial holding × Change in substantial holding
14 August 25	Presentation to the Third Annual Dengue Endgame Summit × Presentation to the Third Annual Dengue Endgame Summit
14 August 25	Date of AGM & Closing Date for Director Nominations × Date of AGM & Closing Date for Director Nominations
11 August 25	Application for quotation of securities - ILA × Application for quotation of securities - ILA
11 August 25	Cleansing Notice × Cleansing Notice
11 August 25	Options exercise from existing substantial shareholder × Options exercise from existing substantial shareholder
31 July 25	Completion of Galidesivir transaction × Completion of Galidesivir transaction
28 July 25	Investor Presentation and investor roadshow × Investor Presentation and investor roadshow
25 July 25	Change of Director's Interest Notice - JC × Change of Director's Interest Notice - JC
24 July 25	Quarterly Appendix 4C and Activities Report × Quarterly Appendix 4C and Activities Report
17 July 25	Options exercise from existing substantial shareholder × Options exercise from existing substantial shareholder
17 July 25	Change in substantial holding × Change in substantial holding
16 July 25	Application for quotation of securities - ILA × Application for quotation of securities - ILA
16 July 25	Cleansing Notice × Cleansing Notice
09 July 25	Portfolio expansion achieved with acquisition of Galidesivir × Portfolio expansion achieved with acquisition of Galidesivir
09 July 25	Investor presentation × Investor presentation

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Falling Divs over next 2

Values and Recommendations

Key Stats

Consensus Score

Recommendation

EPS 1 month Change

Quality Yield

Falling Divs over next 2

Halo Consensus Score

PEG Ratio

Consensus EPS Revisions

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ILA Shortsell

Frequently Asked Questions

What is the current share price of Island Pharmaceuticals Ltd (ILA:ASX)?

The current share price of Island Pharmaceuticals Ltd (ILA:ASX) is AU$0.36.

What is the 52-week high share price for Island Pharmaceuticals Ltd (ILA:ASX)?

The 52-week high share price for Island Pharmaceuticals Ltd (ILA:ASX) is AU$0.38.

What is the 52-week low share price for Island Pharmaceuticals Ltd (ILA:ASX)?

The 52-week low share price for Island Pharmaceuticals Ltd (ILA:ASX)? is AU$0.08.

What is the dividend yield for Island Pharmaceuticals Ltd (ILA:ASX)?

Island Pharmaceuticals Ltd (ILA:ASX) does not pay a dividend.

What was Island Pharmaceuticals Ltd (ILA:ASX) last dividend payment?

Island Pharmaceuticals Ltd (ILA:ASX) does not pay a dividend.

What is the franking level for Island Pharmaceuticals Ltd (ILA:ASX)?

Island Pharmaceuticals Ltd (ILA:ASX) has a franking level of 0.0%.

In which sector is Island Pharmaceuticals Ltd (ILA:ASX) classified?

Island Pharmaceuticals Ltd (ILA:ASX) is classified in the Healthcare.

The current P/E ratio for Island Pharmaceuticals Ltd (ILA:ASX) is .